SELLAS Life Sciences (SLS) EBITDA (2010 - 2026)
SELLAS Life Sciences (SLS) reported EBITDA of -$9.3 million for Q1 2026, down 52.6% year-over-year from -$19.5 million in Q1 2025, and down 12.08% on a QoQ basis from -$8.3 million in Q4 2025.
SELLAS Life Sciences (SLS) has 15 years of EBITDA data on file, last reported at -$9.3 million in Q1 2026.
- Quarterly EBITDA fell 52.6% year-over-year to -$9.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$31.5 million (down 12.65% YoY) and the FY2025 annual result came in at -$28.3 million, up 10.28% from the prior year.
- EBITDA declined to -$9.3 million in Q1 2026 per SLS's latest filing, from -$8.3 million in the prior quarter.
- Across five years, EBITDA topped out at -$6.1 million in Q1 2025 and bottomed at -$16.7 million in Q1 2022.
- The 5-year median for EBITDA is -$8.3 million (2025), against an average of -$8.8 million.
- The widest annual swing landed in 2022, when EBITDA sank 645.43%; it then soared 37.14% in 2025.
- Tracing SLS's EBITDA over 5 years: stood at -$9.4 million in 2022, then climbed by 13.43% to -$8.2 million in 2023, then increased by 15.4% to -$6.9 million in 2024, then fell by 19.33% to -$8.3 million in 2025, then decreased by 12.08% to -$9.3 million in 2026.
- Per Business Quant, the three latest SLS EBITDA figures stand at -$9.3 million (Q1 2026), -$8.3 million (Q4 2025), and -$7.1 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -13.63 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.44 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 661.60 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 201.19 Mn |
| 10 | SELLAS Life Sciences | 1.61 Bn | 1.61 Bn | - | -9.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.25 Mn |
| Dec 31, 2025 | -8.26 Mn |
| Sep 30, 2025 | -7.08 Mn |
| Jun 30, 2025 | -6.87 Mn |
| Mar 31, 2025 | -6.06 Mn |
| Dec 31, 2024 | -6.92 Mn |
| Sep 30, 2024 | -7.33 Mn |
| Jun 30, 2024 | -7.62 Mn |
| Mar 31, 2024 | -9.65 Mn |
| Dec 31, 2023 | -8.18 Mn |
| Sep 30, 2023 | -9.36 Mn |
| Jun 30, 2023 | -9.05 Mn |
| Mar 31, 2023 | -11.28 Mn |
| Dec 31, 2022 | -9.45 Mn |
| Sep 30, 2022 | -7.15 Mn |
| Jun 30, 2022 | -8.62 Mn |
| Mar 31, 2022 | -16.74 Mn |
| Dec 31, 2021 | -11.62 Mn |
| Sep 30, 2021 | -6.98 Mn |
| Jun 30, 2021 | -4.45 Mn |
| Mar 31, 2021 | -2.25 Mn |
| Dec 31, 2020 | -4.16 Mn |
| Sep 30, 2020 | -4.49 Mn |
| Jun 30, 2020 | -4.27 Mn |
| Mar 31, 2020 | -4.06 Mn |
| Dec 31, 2017 | -8.58 Mn |
| Sep 30, 2017 | -4.46 Mn |
| Jun 30, 2017 | -4.91 Mn |
| Mar 31, 2017 | -5.09 Mn |
| Dec 31, 2016 | 8.74 Mn |
| Sep 30, 2016 | -6.47 Mn |
| Jun 30, 2016 | -9.29 Mn |
| Mar 31, 2016 | -8.97 Mn |
| Dec 31, 2015 | -7.59 Mn |
| Sep 30, 2015 | -8.64 Mn |
| Jun 30, 2015 | -9.08 Mn |
| Mar 31, 2015 | -8.91 Mn |
| Dec 31, 2014 | -9.69 Mn |
| Sep 30, 2014 | -10.57 Mn |
| Jun 30, 2014 | -15.78 Mn |
| Mar 31, 2014 | -11.85 Mn |
| Dec 31, 2013 | -7.00 Mn |
| Sep 30, 2013 | -6.89 Mn |
| Jun 30, 2013 | -7.99 Mn |
| Mar 31, 2013 | -6.61 Mn |
| Dec 31, 2012 | -5.58 Mn |
| Sep 30, 2012 | -5.53 Mn |
| Jun 30, 2012 | 227,000.00 |
| Mar 31, 2012 | -23.54 Mn |
| Jun 30, 2011 | -4.62 Mn |
| Jun 30, 2010 | -4.75 Mn |